A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Boehringer Ingelheim

ClinicalTrials.gov Identifier:

NCT01647711

First received: July 16, 2012

Last updated: December 21, 2015

Last verified: December 2015

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	September 2015
Primary Completion Date:	September 2015 (Final data collection date for primary outcome measure)